FluoGuide has submitted a Clinical Trial Application (CTA) to the Danish Medicines Agency to initiate phase II trial with FG001 in head and neck cancer

Copenhagen, Denmark 23 August2022– FluoGuide A/S (“FluoGuide” or the “Company”) is delighted to announce that the company has submitted a CTA to initiate a phase II trial in head and neck cancer. The clinical trial will be conducted at Rigshospitalet in Denmark.

The release as fetched from its publisher. fluoguide.com ↗